Evidence map›Paper›PMID 30964323›Full record

ArticleEnvironmental health perspectives2019

The Carcinogenome Project: In Vitro Gene Expression Profiling of Chemical Perturbations to Predict Long-Term Carcinogenicity.

Amy Li, Xiaodong Lu, Ted Natoli, Joshua Bittker, Nisha S Sipes, Aravind Subramanian, Scott Auerbach, David H Sherr, Stefano Monti

Open access · diamondAbstract read
In one paragraph

Article in Environmental health perspectives, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Amy Li1 Computational Biomedicine, Boston University School of Medicine , Boston, Massachusetts, USA.
Xiaodong Lu3 Cancer Program, Broad Institute of MIT and Harvard , Cambridge, Massachusetts, USA.
Ted Natoli3 Cancer Program, Broad Institute of MIT and Harvard , Cambridge, Massachusetts, USA.
Joshua Bittker3 Cancer Program, Broad Institute of MIT and Harvard , Cambridge, Massachusetts, USA.
Nisha S Sipes4 Toxicoinformatics Group, National Institute of Environmental Health Sciences , Durham, North Carolina, USA.
Aravind Subramanian3 Cancer Program, Broad Institute of MIT and Harvard , Cambridge, Massachusetts, USA.
Scott Auerbach4 Toxicoinformatics Group, National Institute of Environmental Health Sciences , Durham, North Carolina, USA.
David H Sherr5 Department of Environmental Health, Boston University School of Public Health , Boston, Massachusetts, USA.
Stefano Monti1 Computational Biomedicine, Boston University School of Medicine , Boston, Massachusetts, USA.
Broad Institute · USBoston University · USNational Institute of Environmental Health Sciences · US

Funding

Training CoreP42ES007381 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SHERR, DAVID H · 1995 to 2019
$46.1M
Biomolecular Screening and Alternative Approaches for the National Toxicology ProgramZIAES103318 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CASEY, WARREN · 2016 to 2021
$25.0M
There and Back Again: Epigenetic Reinforcement of Cellular Signaling States - OverallU54HG008097 · NHGRI · BROAD INSTITUTE, INC. · PI JAFFE, JACOB DAVID · 2014 to 2019
$9.3M
LINCS Data Coordination and Integration CenterU01HG008699 · NHGRI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R., SUBRAMANIAN, ARAVIND · 2015 to 2019
$3.2M
NHGRI NIH HHS U01 HG008699NHGRI NIH HHS U54 HG008097NIEHS NIH HHS P42 ES007381
6 · The paper itself

Abstract

backgroundMost chemicals in commerce have not been evaluated for their carcinogenic potential. The de facto gold-standard approach to carcinogen testing adopts the 2-y rodent bioassay, a time-consuming and costly procedure. High-throughput in vitro assays are a promising alternative for addressing the limitations in carcinogen screening.

objectivesWe developed a screening process for predicting chemical carcinogenicity and genotoxicity and characterizing modes of actions (MoAs) using in vitro gene expression assays.

methodsWe generated a large toxicogenomics resource comprising [Formula: see text] expression profiles corresponding to 330 chemicals profiled in HepG2 (human hepatocellular carcinoma cell line) at multiple doses and replicates. Predictive models of carcinogenicity and genotoxicity were built using a random forest classifier. Differential pathway enrichment analysis was performed to identify pathways associated with carcinogen exposure. Signatures of carcinogenicity and genotoxicity were compared with external sources, including Drugmatrix and the Connectivity Map.

resultsAmong profiles with sufficient bioactivity, our classifiers achieved 72.2% Area Under the ROC Curve (AUC) for predicting carcinogenicity and 82.3% AUC for predicting genotoxicity. Chemical bioactivity, as measured by the strength and reproducibility of the transcriptional response, was not significantly associated with long-term carcinogenicity in doses up to [Formula: see text]. However, sufficient bioactivity was necessary for a chemical to be used for prediction of carcinogenicity. Pathway enrichment analysis revealed pathways consistent with known pathways that drive cancer, including DNA damage and repair. The data is available at https://clue.io/CRCGN_ABC , and a portal for query and visualization of the results is accessible at https://carcinogenome.org . DISCUSSION: We demonstrated an in vitro screening approach using gene expression profiling to predict carcinogenicity and infer MoAs of chemical perturbations. https://doi.org/10.1289/EHP3986.

Indexed as

Area Under CurveCarcinogenicity TestsCarcinogensDNA DamageGene Expression ProfilingHep G2 CellsHumansIn Vitro TechniquesROC CurveToxicogeneticsCarcinogens

Identifiers

PMID30964323
PMCPMC6785232
OpenAlexW2951366376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.